Clinical trials
Lymphoma, T-Cell, Peripheral trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 9 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 7 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 45 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ruijin Hospital | 6 |
| Peking Union Medical College Hospital | 3 |
| Peking University | 3 |
| Sun Yat-sen University | 3 |
| Fudan University | 2 |
| Henan Cancer Hospital | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, T-Cell, Peripheral | 45 |
| Recurrence | 7 |
| Immunoblastic Lymphadenopathy | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, Large-Cell, Anaplastic | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Lymphoma, T-Cell | 2 |
| Enteropathy-Associated T-Cell Lymphoma | 1 |
| Hodgkin Disease | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.